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Abstract
Background: This pilot study investigated changes in remyelinating and demyelinating activity in normal appearing brain
tissue (NABT) and lesions, by using voxel-wise magnetization transfer ratio (VW-MTR), in patients with relapsing–remitting
multiple sclerosis (RRMS) receiving interferon beta-1a 44 mcg subcutaneously (IFN b-1a SC) three times weekly versus
healthy controls (HCs) (NCT01085318).
Methods: Increasing (suggestive of remyelination) and decreasing (suggestive of demyelination) VW-MTR changes in NABT
and in T2, T1 and gadolinium (Gd)-enhancing lesion volume were measured over 24 weeks in 23 patients treated with IFN b-1a
SC and in 15 HCs (where applicable). VW-MTR changes were tested using the Wilcoxon signed–rank or Wilcoxon rank–sum test.
Results: A trend for greater volume of NABT with increasing VW-MTR at 24 weeks was observed for patients versus HCs
(median [range] 1206 [0–15278]; 342 [0–951] mm3; p = 0.061). NABT volume with increasing VW-MTR at 12 weeks was
significantly greater in patients than in HCs (852 [6–11577]; 360 [0–1755] mm3; p = 0.028). Similar findings were detected for
lesion volumes. Two patients with notably high numbers of Gd-enhancing lesions at baseline had a markedly greater
volume of tissue with increasing VW-MTR compared with other patients. Volume of NABT tissue with decreasing VW-MTR
was significantly greater in patients versus HCs at 24 weeks (942 [0–6141]; 297 [0–852] mm3; p,0.001).
Conclusions: The significant change in NABT volume with increasing VW-MTR at 12 weeks suggests that active
remyelination in patients with RRMS may occur during treatment with IFN b-1a SC. Findings from two patients with the
highest number of Gd-enhancing lesions at baseline suggest that extensive remyelination in NABT may occur in patients
with high disease activity. Tissue volume with decreasing VW-MTR was greater in patients than in HCs, despite treatment,
validating the sensitivity of this technique for detecting MS disease activity.
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Introduction
The hallmarks of multiple sclerosis (MS) are inflammation and
neurodegeneration, with the ongoing processes of demyelination
and remyelination occurring both focally, in central nervous
system lesions, and diffusely, in normal appearing brain tissue
(NABT) [1–3]. Magnetization transfer ratio (MTR) analysis of
myelin content allows quantitative detection of processes in the
brain suggestive of demyelination and remyelination in vivo, by
measuring and quantifying the degree of signal loss at each voxel
[4–6]. However, conventional MTR analysis relies on a priori
location assumptions, and is therefore insensitive to changes that
might occur outside of the predefined boundaries. Importantly, the
technique is sensitive only to mean change in the analyzed area
rather than for the overall level of activity; this creates a scenario
where in many a priori regions of interest (ROI), competing
processes of demyelination and remyelination may cancel each
other out, resulting in a measurement falsely suggesting a lack of
disease activity [7,8].
In contrast, voxel-wise MTR (VW-MTR) analysis is an
advanced image processing technique that measures each voxel
independently and assesses direction and degree of change, thus
avoiding the need for defining a priori ROI. This process also
increases the chance to detect competing processes of demyelin-
ation and remyelination in vivo, allowing a more in-depth
understanding of the dynamism of MS disease processes [4,7–
11]. In addition, tracking VW-MTR changes may provide a
means for integrating information about a variety of tissue changes
not individually detectable with any other single magnetic
resonance imaging (MRI) modality [7,8].
Remyelination usually occurs, to a variable extent, over several
months following lesion formation [10]. Early stages of remyelina-
tion were observed in patients with acute or early MS, whereas
remyelination in later progressive MS was thought to be sparse, with
varying degrees of remyelination competing with demyelination in
MS lesions. In secondary-progressive MS, more demyelination and
higher brain lesion volume (LV) of active demyelination were
observed, compared with patients with primary-progressive
MS [12]. Goldschmidt et al. also reported significantly more
Figure 1. Subject numbers from enrollment to study completion. HC, healthy control; MRI, magnetic resonance imaging.
doi:10.1371/journal.pone.0091098.g001
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remyelinated lesions in biopsies of patients with early MS compared
with autopsy cases of chronic MS [13]. Conversely, histopatholog-
ical analysis of autopsied, completely and partially remyelinated
lesions, conducted by Patrikios et al., showed that remyelination
was not restricted to early stages of the disease and did occur in
progressive MS [14].
In murine models, myelin loss, macrophage infiltration, axonal
damage and increase in water content are manifested as
decreasing MTR, whereas increasing MTR may result from
remyelination, although potential decreases in water content may
also play a role [5,15–17]. However, in six patients with relapsing–
remitting MS (RRMS) and acute gadolinium (Gd)-enhancing
lesions, while the edema in the acute lesions attenuated the
decrease in MTR, a strong correlation between the changes in
MTR and myelin content remained [18]. Several studies describe
the extent of increases and decreases of VW-MTR signal within
NABT as suggestive of remyelinating and demyelinating processes,
respectively, in MS following treatment with immunomodulatory
therapy [7,8,10,16]. Pivotal and subsequent clinical trials showed
that interferon beta-1a (IFN b-1a) given subcutaneously (SC) three
times weekly (tiw) at 22 and 44 mcg in patients with RRMS,
decreased inflammatory MRI activity and clinical disease activity,
as measured by reduction of relapses and slowing in progression of
disability [19,20]. However, the effect of IFN b-1a SC on
Table 1. Baseline characteristics of patients and of HCs and study drug exposure and compliance throughout the study.
Baseline characteristic Patients n = 23 HCs n = 15 p-value for between-group comparison
Age, years, mean (SD) 39.9 (10.17) 36.7 (10.31) 0.362a
Female, n (%) 14 (61) 8 (53) 0.743b
Race, n (%) 0.144b
White 20 (87) 14c (93)
Black 3 (13) 0
Other: Indian 0 1 (7)
Weight, kg, mean (SD) 79.9 (22.25) 87.0 (18.33) 0.313a
Height, cm, mean (SD) 171.0 (8.48) 168.5 (6.99) 0.349a
BMI, kg/m2, mean (SD) 27.2 (6.90) 30.5 (5.37) 0.128a
MS history Patients n = 23
Years since MS diagnosis, mean (SD), range 6.6 (5.65), 0–20
Years since most recent relapse, mean (SD), range 1.0 (1.14), 0.1–5.0










IV Ig 1 (4)
None 3 (13)
EDSS score, median (range) 2.5 (1.0–5.5)
Ambulation distance, meters, mean (SD) 475 (94.2)
Study drug exposure and compliancee IFN b-1a SC tiw n = 23
8.8 mcg 22 mcg 44 mcg
Total dose received, mcg, mean (SD) 52.5 (7.60) 133.9 (9.17) 2174.9 (584.47)
Doses missed, mean (SD) 0 (0.2) 0 (0) 5 (7.6)
Compliance, %, mean (SD) 99 (3.5) 100 (0) 92 12.2)
aFor the difference between groups from the Student’s t-test.
bFor the difference between groups from Fisher’s exact test.
cIncludes one of Hispanic ethnicity, all other subjects were not Hispanic.
dPatients reported the same number of relapses for the past 24 months.
eCompliance was calculated at study visits using subject diaries and returned drug. Exposure was calculated from compliance.
BMI; body mass index; DMD, disease-modifying drug; EDSS, Expanded Disability Status Scale; HC, healthy control; IFN b-1a, interferon beta-1a; IV Ig, intravenous
immunoglobulin; MS, multiple sclerosis; SC, subcutaneous; SD, standard deviation; tiw, three times weekly.
doi:10.1371/journal.pone.0091098.t001
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remyelination and any effect on the demyelination that is expected
to occur in the NABT and lesions of patients with RRMS are
unknown. The present pilot study was designed to investigate
changes in VW-MTR in NABT and lesions in patients with
RRMS receiving 24 weeks of treatment with IFN b-1a SC in
comparison with untreated, healthy controls (HCs).
Objectives
The primary objective was to characterize the effect of 24 weeks
of treatment with IFN b-1a SC on VW-MTR dynamic mapping
of NABT in patients with RRMS with reference to HCs.
Secondary objectives were to characterize the effect of
treatment on VW-MTR dynamic mapping of T2, T1 and Gd-
enhancing lesions in patients over various treatment periods
(baseline to 12 weeks, 12 to 24 weeks, baseline to 24 weeks), and
with reference to HCs. The effect of treatment on VW-MTR
dynamic mapping of NABT and lesions on the first 12 weeks
(baseline to 12 weeks) compared with the second 12 weeks (12 to
24 weeks) was also measured in patients and HCs.
Methods
The protocol for this trial and CONSORT checklist are
available as Checklist S1 and Protocol S1. A 24-week, open-label,
two-arm, single-center pilot trial (ClinicalTrials.gov:
NCT01085318) was conducted in patients with RRMS and in
HCs. Subjects gave written informed consent before participation
in the study. The trial protocol and all major amendments were
approved by the relevant Institutional Review Boards or
Independent Ethics Committees and by Health Authorities. The
trial was conducted in accordance with the protocol, the
International Conference on Harmonization guideline for Good
Clinical Practice, and applicable local regulations as well as with
the Declaration of Helsinki. The protocol was approved by the
University at Buffalo Health Sciences Institutional Review Board.
Screening was performed within 14 days prior to study entry.
Baseline assessments included physical and neurologic exams,
MRI scans and laboratory studies. Study patients had brain MRI
scans on Study Day 1, and at 12 and 24 weeks, with neurologic
examinations conducted at screening and at 12 and 24 weeks. The
MRI analysis was rater-blinded. Neurologic examinations were
not blinded. A safety evaluation telephone call was scheduled 4
weeks post study exit to monitor the subjects’ status.
The main inclusion criteria were: age 18–65 years; diagnosis of
MS according to the revised 2010 McDonald criteria [21]; RRMS
disease course [22], treatment-naı̈ve or currently using any of the
US Food and Drug Administration-approved disease-modifying
drugs; and disease duration of #20 years. Main exclusion criteria
were: plasmapheresis within 3 months prior to screening;
treatment with immunosuppressant agents within 30 days prior
to screening; any other concomitant immunomodulatory thera-
pies; relapse within 30 days prior to screening; steroid treatment
within 30 days prior to MRI on Study Day 1; alanine
aminotransferase .2.56upper limit of normal (ULN), alkaline
phosphatase .2.56ULN or total bilirubin .1.56ULN; total
white blood cell count ,3.06109/L, platelet count ,756109/L
or hemoglobin ,100 g/L; complete transverse myelitis or
simultaneous-onset bilateral optic neuritis; thyroid dysfunction;
moderate to severe renal impairment; history of seizures not
adequately controlled by treatment; and serious or acute cardiac
disease.
Patients received IFN b-1a SC tiw for 24 weeks, titrated over 4
weeks to a final dose of 44 mcg.
Data Collection
MRI exams of the brain were performed on a 3T GE Signa LX
Excite 12.0 scanner. In addition to localizer/scout images and
calibration images, the following scans were acquired: dual echo
proton density (PD) and T2-weighted image (WI), 3D-inversion
recovery fast-spoiled-gradient recalled (IR-FSPGR), T1-WI, spin-
echo (SE) T1-WI with (patients only) and without Gd contrast,
fluid attenuated inversion recovery (FLAIR), PD-weighted (used as
the magnetization transfer unsaturated M0 image) and PD-
weighted with magnetization transfer (MS). Conventional 2D
scans (PD/T2, FLAIR and T1 SE pre- and post-contrast) were
acquired with consistent voxel size (48 slices of 3 mm slice
thickness, with FOV = 25.6, matrix = 2566256 and phase
FOV = .75), and slice selection (oblique axial images parallel to
the subcallosal plane).The PD M0 was acquired with 3 mm slice
thickness, FOV = 25.6, phase FOV = 0.75, matrix 2566256,
TR = 2400, TE = 22 and FA = 90. The PD MS was acquired
identically to the M0 except for the addition of a magnetization
transfer pulse with an offset of 1200 Hz. Patients received a single
dose (0.1 mmol/kg) of Gd contrast. HCs did not receive contrast
injection. All participants were positioned in the scanner to
maximize comfort and minimize head movement. The nasion
landmark was used to position the head in the isocenter of the
magnetic field.
For the primary endpoint, the volumes of NABT with
increasing or decreasing in VW-MTR value from baseline to 24
weeks in patients treated with IFN b-1a SC were compared with
changes in VW-MTR in NABT of HCs. Secondary endpoints
Table 2. Baseline MRI T2, T1 and Gd-enhancing lesion
assessments.
Patients n = 23 HCs n = 15
T2 lesions
Number, mean (SD) 34.9 (24.51) 0.8 (1.37)
Median (range) 28 (5–115) 0 (0–4)
Volume, mm3, mean (SD) 23683 (27731) 57 (151)
Median (range) 17739 (558–118940) 0 (0–588)
T1 lesions
Number, mean (SD) 19.5 (15.34) 0 (0)
Median (range) 19 (0–59) 0 (2)
Volume, mm3, mean (SD) 4532 (5417) 0 (0)
Median (range) 2847 (0–23364) 0 (2)
Gd-enhancing lesions
Number, mean (SD) 1.8 (4.84) –
Median (range) 0 (0–22) –
Volume, mm3, mean (SD) 240 (646) –
Median (range) 0 (0–2915) –





07, 08, 18 1
All others 0
Gd, gadolinium; HC, healthy control; MRI, magnetic resonance imaging; SD,
standard deviation.
doi:10.1371/journal.pone.0091098.t002
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were the volumes of tissue significantly increasing and significantly
decreasing in VW-MTR value from baseline to 12 weeks and from
12 to 24 weeks in NABT, and increasing and decreasing VW-
MTR values at 24 weeks versus baseline in T2, T1 and Gd-
enhancing lesions.
The VW-MTR analysis was previously described in detail [7].
Briefly, the following processes were applied: 1) Lesions were
identified on T2/PD/FLAIR-WI, T1 pre-contrast (black holes)
WI and T1 post-contrast (Gd-enhancing) WI, as previously
described [23]; 2) VW-MTR and accompanying T1-WI, T1+
Figure 2. Change in VW-MTR in NABT from baseline to 24 weeks. The figure depicts a comparison between patients and HCs with A)
increasing VW-MTR and B) decreasing VW-MTR and difference from baseline within each study group for increasing and decreasing VW-MTR in C)
patients and D) HCs. For A) and B), the p value is the difference between patients and HCs from the Wilcoxon rank–sum test; for C) and D), the p-value
is the difference from baseline within groups from the Wilcoxon signed–rank test. In the box plots, the bold line represents the median; the boxes
represent the middle 50% of data; the top and bottom of the box represent the third and first quartiles; the open circles are outliers. The whisker lines
above and below the boxes represent the largest and smallest values that are not considered to be outliers. HC, healthy control; NABT, normal
appearing brain tissue; VW-MTR, voxel-wise magnetization transfer ratio.
doi:10.1371/journal.pone.0091098.g002
Voxel-Wise Magnetization Transfer Ratio in MS
PLOS ONE | www.plosone.org 5 March 2014 | Volume 9 | Issue 3 | e91098
Gd-WI, T2/PD/FLAIR-WI and 3D-T1-WI images were co-
registered using FLIRT (FMRIB, Oxford, UK); 3) 3DT1-WI were
segmented to classify voxels as gray matter, white matter and
cerebrospinal fluid, as well as to eliminate voxels with significant
partial volume changes. Misclassification of T1 hypointensities
were avoided using an in-house-developed inpainting technique; 4)
VW-MTR maps were generated by a voxel-wise application of the
standard MTR formula ([(M0–MS)/M0]6100); 5) VW-MTR
difference maps were created by subtracting VW-MTR map pairs
based on longitudinal time points; 6) Threshold-free cluster
enhancement (TFCE) was applied to the difference maps to
increase classification sensitivity; 7) A Monte Carlo process was
used to derive statistically rigorous probability values associated
with the TFCE-generated voxel clusters; 8) Voxels were classified
as increasing or decreasing in NABT, T2, T1 and T1+Gd lesion
volumes and 9) Image quality control was performed at every
stage, beginning with the quality control of the raw input images.
Frequency and number of adverse events (AEs) in HCs and
patients over the duration of the study were recorded.
Statistical Methods
A total of 40 subjects, comprising 25 patients and 15 HCs, were
planned to be enrolled.
All statistical tests were two-tailed and considered significant at
the a= 0.05 level of significance. Student’s t-tests and Fisher’s
exact tests were used to test for differences in demographic and
clinical characteristics between patients and HCs. Non-parametric
tests were used for comparisons of MRI data, since MRI data were
not expected to be normally distributed. The Wilcoxon rank–sum
test was used for testing the difference between patients and HCs.
The Wilcoxon signed–rank test was used for testing changes from
baseline within study groups and differences across time (i.e., first
12 weeks versus second 12 weeks of the study) within study groups.
If lesion volumes in HCs were not measurable, only comparisons
within the patient group were made. With the exception of the
primary endpoint, which was not corrected?, multiple comparisons
were corrected using the Holm-Bonferroni method.
Results
Study Participants
Twenty one/23 enrolled patients and all 15 HCs completed the
study. Reasons for discontinuations are recorded in Figure 1.
Baseline characteristics of patients and HCs (including history of
pre-study therapies) are shown in Table 1. There were no
significant differences in demographic characteristics between the
study groups. Study drug exposure and compliance during the
study is shown in Table 1.
Between 5 and 16 patients scored as abnormal on various items
of the neurologic assessments. Most HCs scored as normal,
although 2 two HCs scored as abnormal on cranial nerve status
and 1 HC scored as abnormal on reflex and sensory status.
Table 3. Change in VW-MTR in NABT over time – comparison between patients and HCs with increasing and decreasing VW-MTR
(mm3).
Baseline to 12 weeks 12 to 24 weeks Baseline to 24 weeks
Patients HCs Patients HCs Patients HCs
n (missinga) 22 (1) 15 (0) 20 (3) 13 (2) 21 (2) 13 (2)
Increasing VW-MTR (mm3)
Mean (SD) 1467 (2482) 445 (474) 1161 (1325) 420 (459) 2473 (4082) 356 (292)
Median 852 360 764 201 1206 342
Min, Max 6, 11577 0, 1755 0, 4518 36, 1239 0, 15278 0, 951
p-valueb ,0.001 ,0.001 ,0.001 ,0.001 ,0.001 ,0.001
Adjusted p-valueb,c ,0.001 ,0.001 ,0.001 0.001 ,0.001 0.002
p-valued 0.028 NS 0.061
Adjusted p-valuec,d NS NS –
Adjusted p-valuec,e NS/NS
Decreasing VW-MTR (mm3)
Mean (SD) 1349 (1076) 274 (237) 1513 (1974) 388 (349) 1346 (1263) 358 (311)
Median 1092 186 779 279 942 297
Min, Max 279, 4321 3, 822 156, 8499 57, 1263 0, 6141 0, 852
p-valueb ,0.001 ,0.001 ,0.001 ,0.001 ,0.001 ,0.001
Adjusted p-valueb,c ,0.001 ,0.001 ,0.001 0.001 ,0.001 0.001
p-valued ,0.001 0.006 ,0.001
Adjusted p-valuec,d ,0.001 NS –
Adjusted p-valuec,e NS/NS
aFailed analysis or missing MRI at Week 24.
bFor the difference from zero within groups from the Wilcoxon signed–rank test.
cAdjusted for multiple comparisons with the Holm-Bonferroni correction.
dFor the difference between IFN b-1a SC and HC from the Wilcoxon rank–sum test.
eFor the difference between the first 12 weeks and the second 12 weeks within groups from the Wilcoxon signed–rank test (p-value for patients/HCs).
HC, healthy control; IFN b-1a, interferon beta-1a; NABT, normal appearing brain tissue; Max, maximum; Min, minimum; NS, non-significant; SC, subcutaneously; SD,
standard deviation; VW-MTR, voxel-wise magnetic transfer ratio.
doi:10.1371/journal.pone.0091098.t003
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Baseline MRI T2, T1 and Gd-enhancing lesion assessment data
are shown in Table 2. Eight/23 patients (35%) had $1 Gd-
enhancing lesion at baseline; patient ID #29 had the greatest
number of Gd-enhancing lesions.
Change in Volume of NABT with VW-MTR Following 12
and 24 Weeks of Treatment with SC IFN b-1a
The median [range] difference in NABT volume with increase
in VW-MTR from baseline to 24 weeks between patients and HCs
approached significance (1206 [0–15278] and 342 [0–951] mm3,
respectively; p = 0.061, unadjusted) (Figure 2A and Table 3). From
baseline to 12 weeks, there was a significant change in NABT
volume with increasing VW-MTR in patients compared with HCs
(852 [6–11577] and 360 [0–1755] mm3, respectively; p = 0.028,
unadjusted) (Table 3).
Change in NABT volume with decreasing VW-MTR from
baseline to 24 weeks was significantly greater in patients compared
with HCs (942 [0–6141] and 297 [0–852] mm3; p,0.001,
unadjusted (Figure 2B), and at other study timepoints (Table 3).
The median [range] difference in volume of NABT with
decreasing VW-MTR in NABT between patients and HCs
(1092 [279–4321]; 186 [3–822] mm3, respectively) was also
significant (p,0.001, adjusted) from baseline to 12 weeks, but not
significant from 12 to 24 weeks following adjustment (Table 3).
Within the patient group, there was a tendency for a greater
inter-subject variation in volume of NABT with increasing and
decreasing VW-MTR (Figure 2C), while HCs had very similar,
low-level increasing and decreasing VW-MTR (Figure 2D).
In 2 patients, markedly increased VW-MTR volumes in NABT
were observed compared with all other patients (15278 and
12000 mm3) (Figure 3A); these patients also had the highest
number of Gd-enhancing lesions (patient ID #s 29 and 03) at
baseline (Table 2). One patient appeared not to have any
measurable changes in VW-MTR (Figure 3A).
Change in VW-MTR Lesion Volume Following 24 Weeks
of Treatment with IFN b-1a SC
T2-LV. The change in T2-LV was 0 for baseline to 12 weeks
and for baseline to 24 weeks for all HCs. A change in T2-LV with
increasing VW-MTR of 18 mm3 was noted from 12 to 24 weeks in
a single HC (ID #11). Changes in T2-LV with increasing and
decreasing VW-MTR in patients are summarized in Table 4.
Although the median change in T2-LV with increasing VW-MTR
from baseline to 24 weeks for patients was 0, there was a significant
change from baseline for this group (median [range] of 0 [0–4050]
mm3; p = 0.039; adjusted for multiple comparisons) (Figure 4). The
change in T2-LV with decreasing VW-MTR from baseline to 24
weeks was also significant in patients (median [range] of 105 [0–
1722] mm3; p = 0.007, adjusted for multiple comparisons)
(Figure 4). There was a greater degree of change occurring for
T2-LV with decreasing VW-MTR than with increasing VW-
MTR in patients. One patient (patient ID # 29) appeared to have
Figure 3. Change in VW-MTR from baseline to 24 weeks. Change in A) NABT in patients and in HCs, B) T2-LV, T1-LV and Gd-enhancing lesions
in patients only. Gd, gadolinium; HC, healthy control; LV, lesion volume; NABT, normal appearing brain tissue; VW-MTR, voxel-wise magnetization
transfer ratio.
doi:10.1371/journal.pone.0091098.g003
Table 4. Change in T2-LV and T1-LV over time in patients with increasing and decreasing VW-MTR (mm3).
T2-LV T1-LV
Baseline to 12 weeks
12 to 24
weeks Baseline to 24 weeks Baseline to 12 weeks
12 to 24
weeks Baseline to 24 weeks
n (missinga) 22 (1) 20 (3) 21 (2) 22 (1) 20 (3) 21 (2)
Increasing VW-MTR (mm3)
Mean (SD) 189 (641) 78 (225) 330 (900) 114 (430) 63 (206) 176 (478)
Median 3 0 0 0 0 0
Min, Max 0, 3033 0, 1008 0, 4050 0, 2022 0, 924 0, 2058
p-valueb ,0.001 0.004 0.004 0.008 0.063 0.004
Adjusted p-valueb,c 0.012 0.043 0.039 NS NS 0.035
Adjusted p-valuec,d NS – NS –
Decreasing VW-MTR (mm3)
Mean (SD) 228 (594) 127 (202) 278 (420) 95 (245) 61 (113) 91 (149)
Median 149 27 105 45 0 33
Min, Max 0, 2844 0, 786 0, 1722 0, 1173 0, 456 0, 621
p-valueb ,0.001 ,0.001 ,0.001 ,0.001 0.004 ,0.001
Adjusted p-valueb,c 0.002 0.004 0.007 0.007 0.031 0.006
Adjusted p-valuec,d NS – NS –
aFailed analysis or missing MRI at Week 24.
bFor the difference from zero within groups from the Wilcoxon signed–rank test.
cAdjusted for multiple comparisons with the Holm-Bonferroni correction.
dFor the difference between the first 12 weeks and the second 12 weeks from the Wilcoxon signed–rank test.
LV, lesion volume; Max, maximum; Min, minimum; MRI, magnetic resonance imaging; NS, non-significant; SD, standard deviation; VW-MTR, voxel-wise magnetic transfer
ratio.
doi:10.1371/journal.pone.0091098.t004
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a very high (4050 mm3) amount of increasing VW-MTR. Outliers
in T2-LV with decreasing VW-MTR were not as pronounced,
with an outlier (patient ID # 08) at 1722 mm3. Six patients did
not appear to have any T2-LV with increasing or decreasing VW-
MTR; whereas 6 patients had both; 3 patients had T2-LV with
increasing VW-MTR only and 6 patients had T2-LV with
decreasing VW-MTR only (Figure 3B).
T1-LV. There was no change in T1-LV for all HCs for all
timepoint comparisons. Changes in T1-LV with increasing and
decreasing VW-MTR in patients are summarized in Table 4.
Similar to T2-LV, the median change in T1-LV with increasing
VW-MTR from baseline to 24 weeks for patients was 0, yet there
was a significant change from baseline for this group (median
[range] of 0 [0–2058] mm3; p = 0.035; adjusted for multiple
comparisons [Figure 5]; mean [standard deviation (SD)] increase
176 [478] mm3.).
Although the distributions of increasing and decreasing VW-
MTR for T1-LV for baseline to 24 weeks are more similar than
they were for T2-LV, more extreme outliers were again observed
in T1-LV for increasing VW-MTR than for decreasing VW-
MTR. Patient ID # 29 had an outlier volume of increasing VW-
MTR of 2058 mm3 and a decreasing volume of VW-MTR of
72 mm3 in T1-LV. T1-LV with increasing VW-MTR was not
detected in the patient with the greatest volume of decreasing VW-
MTR in T1 lesions (621 mm3 in patient ID # 08; Figure 3B). As
with T2-LV, 6 patients did not appear to have any volumes of
increasing or decreasing VW-MTR in T1-LV from baseline to 24
weeks, whereas 6 patients had both, 3 patients had T1-LV with
increasing VW-MTR only and 6 patients had T1-LV with
decreasing VW-MTR only.
Gd-enhancing-LV. For HCs, measurement of Gd-enhancing
LV was not performed. There were no significant changes from
baseline of either increasing or decreasing VW-MTR in Gd-
enhancing LV. Of the 8 patients who had Gd-enhancing lesions at
baseline, 2 patients had notably higher amounts of increasing VW-
MTR compared with other patients (patient ID #29 and 03).
Fifteen patients had neither increasing nor decreasing VW-MTR
in Gd- enhancing LV from baseline to 24 weeks; increasing and
decreasing VW-MTR of Gd-enhancing LV were both observed in
only 1 patient (patient ID # 29). Three patients had only
increasing VW-MTR in Gd-enhancing LV and 2 patients had
only decreasing VW-MTR (Figure 3B).
Differences in VW-MTR across Time Points
The differences in volume of NABT, T2 and T1 lesions with
increasing VW-MTR between the first 12 weeks and the second
12 weeks of the study in patients were not significant following
adjustment for multiple comparisons (Tables 3 and 4). This was
also the case for decreasing VW-MTR.
Relapses
In total, 5/23 (22%) patients had eight relapses; 4 patients (ID
#s 09, 17, 23 and 43) each had one relapse of moderate severity
and 1 patient (ID # 07) had four relapses, three of moderate
severity and one of mild severity (recorded as a serious AE
following exposure to treatment) (Table 5).
Safety
The majority of patients (22/23) had $1 AE; 16 patients were
considered to have had AEs related to study treatment.
Frequencies of AEs are summarized in Table 6. The most
commonly occurring ($3) treatment-emergent AEs in the patients
included influenza-like illness and injection-site reaction.
Discussion
The primary objective of this pilot study was to investigate the
effects of IFN b-1a SC treatment over 24 weeks on VW-MTR
volume changes in NABT in patients with RRMS. Secondary
objectives were the measurement of changes in VW-MTR LV
over 24 weeks and in NABT from baseline to 12 weeks and from
12 to 24 weeks following treatment with IFN b-1a SC, as well as
safety.
The increases and decreases in VW-MTR observed in the study
serve as indications of possible remyelinating and demyelinating
processes occurring in NABT, T2, T1 and Gd-enhancing lesions of
patients [7]. For NABT, increases in VW-MTR in patients were
much greater than those observed in HCs, but the variation was
such that the difference fell short of significance at 24 weeks. It is
possible that loss of statistical power by 24 weeks contributed to this
result, as MRI data for 2 patients and 2 HCs were not available for
the Week 24 comparison, thus reducing the already small sample
size available for statistical analysis. From baseline to 12 weeks,
NABT tissue volume with increasing VW-MTR was significantly
greater in patients compared with HCs (unadjusted p-value), which
could suggest that IFN b-1a SC treatment may be associated with
an early surge in remyelinating activity. This is consistent with
the effect of type I IFNs suggested in a virus-infected SJL/J
mouse model of MS (Theiler’s murine encephalomyelitis), in which
Figure 4. Difference from baseline to 24 weeks for increasing
and decreasing VW-MTR in T2-LV in patients. The p-value is for
the difference from zero within groups from the Wilcoxon signed–rank
test with adjustment. In the box plot, the bold line represents the
median; the boxes represent the middle 50% of data; the top and
bottom of the box represent the third and first quartiles; the open
circles are outliers. The whisker lines above and below the boxes
represent the largest and smallest values that are not considered to be
outliers. LV, lesion volume; NS, not significant; VW-MTR, voxel-wise
magnetization transfer ratio.
doi:10.1371/journal.pone.0091098.g004
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short-term treatment (5 weeks) led to a significant increase in
remyelinated spinal cord white matter [24].
When the data from individual patients were analyzed, the large
variations observed are attributed to very high increasing VW-
MTR volumes in 3 patients (ID #s 29, 03, 25). Similarly, for T2
lesions, increases in VW-MTR appeared to be driven by a small
number of patients. The sensitivity of the VW-MTR imaging
technique enabled the distinction of this subpopulation of patients,
and suggested that remyelination in these patients was very
prominent. However, the results need to be verified by a larger
study.
The between-patient variability in tissue volume with changing
VW-MTR is consistent with previous VW-MTR studies [8]. A
profound diversity in the amount of remyelination between cases
has also been observed by immunohistochemistry, with evidence
of extensive remyelination occurring in RRMS and progressive
disease [14]. As histopathological analysis of a Gd-enhancing
lesion has been shown to correlate with VW-MTR [11], further
validation of VW-MTR extrapolation to remyelination and
demyelination by histopathology may help better define this
relationship [25].
Baseline disease activity may affect treatment response; having a
high number of Gd-enhancing lesions was expected to result in
little increasing VW-MTR activity in NABT [11]. However, the 2
patients (ID #s 29, 03) with the greatest number of Gd-enhancing
lesions at baseline (22 and 9 lesions, respectively) had markedly
increased VW-MTR changes in NABT, suggesting that higher
inflammatory activity may correlate with much higher remyelina-
tion. From this study, definitive conclusions cannot be drawn as to
whether IFN b-1a SC treatment caused the observed higher
remyelination, as untreated patients were not studied. However,
the results are intriguing and it is interesting to speculate that IFN
b-1a SC may be exerting an anti-inflammatory effect, which is
then influencing the remyelination process. Investigations of
correlations between the effect of IFN b-1a SC on Gd-enhancing
lesions and VW-MTR changes would be interesting. An
explanation for those patients where increasing VW-MTR activity
was sparse might be that prior repeated demyelinating and
remyelinating processes within lesions could have destroyed
oligodendrocyte progenitor cells, leading to inhibition of progen-
itor cell maturation [26,27] or axonal inhibition of remyelination
[28].
Of the 5 patients who had a relapse during the study, VW-
MTR changes in NABT and LV were moderate to small, or
negligible in magnitude, relative to patients without relapse.
Generally, decreasing VW-MTR appeared to be more prominent
than increasing VW-MTR in the 4 patients who each had one
relapse. For the patient with four relapses (ID # 07), VW-MTR
changes were small; notably, decreasing VW-MTR was dominant
over increasing VW-MTR in NABT, while increasing VW-MTR
was greater than decreasing VW-MTR in T2-LV, T1-LV and Gd-
enhancing LV.
As expected, decreasing VW-MTR in NABT measured versus
baseline at 12 and 24 weeks and in T2-LV at 24 weeks was
significantly greater in patients than in HCs, supporting the
validity and sensitivity of the VW-MTR imaging technique for
measuring ongoing demyelinating processes in the RRMS disease
state.
Factors Affecting Measurement of Myelin Content by
VW-MTR
The significant changes from baseline to 24 weeks in VW-MTR
activity in NABT volume within both the patient and HC groups
and in T2-LV and T1-LV within the patient group are suggestive
of dynamic shifts occurring in myelin content. It then follows that a
numerically greater degree of change in VW-MTR signal
occurred in patients than in HCs in all areas measured is
suggestive of greater dynamic shifts in myelin content. The reasons
for this are unknown but are assumed to be due to the RRMS
disease state, although, without an untreated control RRMS
group, an effect due to treatment with IFN b-1a SC cannot be
Figure 5. Difference from baseline to 24 weeks for increasing
and decreasing VW-MTR in T1-LV in patients. The p-value is for
the difference from zero within groups from the Wilcoxon signed–rank
test with adjustment. In the box plots, the bold line represents the
median; the boxes represent the middle 50% of data; the top and
bottom of the box represent the third and first quartiles; the open
circles are outliers. The whisker lines above and below the boxes
represent the largest and smallest values that are not considered to be
outliers. LV, lesion volume; VW-MTR, voxel-wise magnetization transfer
ratio.
doi:10.1371/journal.pone.0091098.g005
Table 5. Relapses occurring in patients during the study.
Patients n = 23
Time to first relapse months,
mean (SD), range
2.5 (1.88), 0–4 months
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ruled out. It has to be noted that subtle movement artifacts may be
an important confounding source in the VW-MTR analysis.
However, we believe we have adequately controlled for this in two
ways. First, motion artifacts tend to create high-frequency,
disconnected ‘‘ridges’’, which are not generally picked up by the
TFCE approach that we used to preprocess the data. Second, and
more directly, we specifically included motion artifacts in our
quality control checks, and manually removed them if detected.
The VW-MTR imaging technique has advantages over
conventional MRI because its voxel-wise approach to image
processing avoids the definition of a priori ROIs inherent to other
MRI approaches, thereby reducing background noise and
increasing sensitivity to a level capable of reporting on more
subtle or heterogeneous tissue changes (e.g., myelination processes
in NABT) not normally detectable by ROI-based approaches. On
the other hand, potential confounding influences on the sensitivity
of VW-MTR to myelination processes in lesions may result from
rapid, transient changes in re- and demyelination events and to the
associated edema that accompanies inflammation during the acute
period of lesion formation. In the brains of 7 patients with MS,
significant correlation was found between water content and
MTR, indicating that inflammation and edema influence MTR in
those patients, and so decreasing MTR may not be exclusively due
to demyelination [29]. However, post-lesion MTR values appear
to stabilize after 6 months [10], giving confidence that mean MTR
changes are unlikely to be affected by transient inflammation and
edema and better reflect pure myelination processes after this time
point. The changes in the NABT VW-MTR due to edema
resolution are even less likely after 6 months. Edema itself may
correlate poorly with myelin content; the conclusion from an ex vivo
study in rat spinal cord was that intercompartmental exchange of
water between myelin and non-myelin compartments may cause
the myelin water fraction to underestimate the true myelin content
of tissue. However, MTR metrics appear to be insensitive to
intercompartmental water exchange in comparisons with multi-
exponential T2 relaxation MRI measures [30]. In an experimental
autoimmune encephalomyelitis model [31], MTR and myelin
water percentage appeared to measure different aspects of
pathology, and modulation of inflammatory activity did not
correlate with myelin water percentage.
Safety
There were no unexpected AEs reported following treatment
with IFN b-1a SC, which was well-tolerated by patients in this
study. Injection-site reactions and influenza-like illness were, as
expected, the most commonly occurring AEs, consistent with
previous studies where these events were also noted as common
AEs [19,20,32].
Limitations of this Study
The myelin specificity of VW-MTR and the evidence from
previous studies suggesting that increases in VW-MTR may be
attributed to remyelination in MS [7,8,10,16] should be consid-
ered with some caution, as there does not yet appear to be a well-
accepted MRI metric of remyelination [33]. The use of VW-MTR
as a possible indication of remyelination is still an emerging
technique; further validation is required to discount confounding
effects as described above that could cause increasing tissue
volumes that are detected by VW-MTR.
The potential benefit of IFN b-1a SC on remyelination as
measured by VW-MTR in a head-to-head comparison with
untreated or comparator-treated patients was not measured.
However, the inclusion of a HC group allowed evaluation of this
technique for normal variation between individuals, against which
changes in VW-MTR could be compared. Use of HCs for
comparison with a patient population in prospective longitudinal
pilot studies of non-conventional MRI, including VW-MTR, may
become an attractive approach in the future for several reasons.
First, the ultimate goal of therapy is to normalize patient VW-
MTR changes over time or to reduce variability over time, to
those observed in HCs over the same time period. HCs also
experience brain changes over time and so the notion of arresting
disease progression as measured by VW-MTR requires validation
by reference to a comparator without disease progression to
account for age-related changes. Second, ethical considerations
preclude placebo-controlled studies using an established MS
treatment versus placebo-treatment in patients with RRMS. An
alternative would be to measure VW-MTR prior to starting
treatment; however, this is more difficult from a practical and
ethical point of view, as the window of switching from old to new
treatments is very narrow in patients with MS at present time and
the feasibility of enrolling sufficient numbers of patients with MS
who were naı̈ve to treatment was deemed to be low.
Another limitation that should be considered in any future study
is that transient, intermittent, and/or longer term effects of
treatment with IFN b-1a SC may have been missed by the short
duration and limited number of VW-MTR measurement time-
points of this pilot study. As already mentioned, early stage
remyelination events occurring in lesions that are still active may
be unstable [10], so that formation of persistent, remyelinated
shadow plaques earlier in the disease time course will be sparse in
contrast to what is observed in inactive lesions of later-stage disease
[14]. Previously, a 1-year study was extended to a 2-year follow-up
due to evidence of the sensitivity of VW-MTR as a means to
monitor disease activity in patients with MS [8]. Significant
increases and decreases in MTR have been shown to be ongoing






$1 AE 22 (96) 8 (53)
$1 treatment-related AEa 16 (70) 0
$1 severe AE 4 (17) 0
$1 serious AE 1 (4) 0
$1 AE resulting in discontinuation
of study drugb
1 (4) 0
Most common ($3) TEAEs, n (%) Patients
n = 23
Influenza-like illness 9 (39)
Injection-site reaction 8 (35)
Multiple sclerosis relapse 5 (22)
Fatigue 4 (17)




Muscular weakness 3 (13)
Nausea 3 (13)
aRelationship = possible, probable.
bAction taken = medication permanently stopped.
AE; adverse event; HC, healthy control; TEAE, treatment-emergent AE.
doi:10.1371/journal.pone.0091098.t006
Voxel-Wise Magnetization Transfer Ratio in MS
PLOS ONE | www.plosone.org 11 March 2014 | Volume 9 | Issue 3 | e91098
for 7 and 33 months, respectively, in a 3-year study on various
regions of acute Gd-enhancing lesions [4]. As potential remyelina-
tion follows onset of demyelination [14], a future study design with
more frequent VW-MTR measurement timepoints to measure the
relative time courses of VW-MTR decreases and increases may
capture the temporal signature of RRMS. A benefit of a longer-
term study measuring sustained remyelinating effects, in addition
to gaining insights on whether and how IFN b-1a SC influences
re- and demyelination, would be to minimize any bias in
interpretation of VW-MTR measurement by transient fluid shifts.
As the magnitude of change from baseline to Week 24 is larger
than from baseline to Week 12, enrollment of larger patient and
HC populations in future studies would allow for adequate power
to detect interesting signals, and would also allow for better
characterization of the localizations of VW-MTR changes. Given
the small sample and relatively short follow-up, the study was not
sufficiently powered to perform spatial mapping of changes in a
meaningful way. However, in the previous study, we noted
possible regional specificity of the localizations of VW-MTR
changes with increases in VW-MTR being more confined to the
frontal lobes and the decreases in VW-MTR being more confined
to the parietal and occipital lobes [8].
Conclusions
A significant change in NABT volume with increasing VW-
MTR was observed in patients with RRMS following treatment
with IFN b-1a SC tiw at 12 weeks. Further studies are required to
investigate this as a possible treatment effect. This study further
validates VW-MTR as a potentially valuable and sensitive tool for
understanding the complicated pathological processes underlying
RRMS. The considerable patient-dependent variability in VW-
MTR changes in NABT and lesion volumes suggests that there
may be heterogeneity in the population examined, which would
merit further research in a larger and longer-term study to
understand potential correlations between advanced MRI activity,
disease activity and duration and relapses. In particular, it would
be valuable to identify patients who would benefit most from MS
therapies like IFN b-1a SC in terms of remyelination and whether
the significant increase in VW-MTR signal suggestive of
remyelinating activity in patients seen at 12 weeks can be
sustained long-term.
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